ICCC vs. LYEL, HURA, ZNTL, NLTX, CRGX, VXRT, ACRV, CDTX, ALEC, and ACRS
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Lyell Immunopharma (LYEL), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Neoleukin Therapeutics (NLTX), CARGO Therapeutics (CRGX), Vaxart (VXRT), Acrivon Therapeutics (ACRV), Cidara Therapeutics (CDTX), Alector (ALEC), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.
ImmuCell vs.
ImmuCell (NASDAQ:ICCC) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends.
ImmuCell has a net margin of -15.99% compared to Lyell Immunopharma's net margin of -323,792.09%. ImmuCell's return on equity of -15.32% beat Lyell Immunopharma's return on equity.
ImmuCell has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 6.6% of ImmuCell shares are held by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ImmuCell received 107 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
ImmuCell has higher revenue and earnings than Lyell Immunopharma. ImmuCell is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Lyell Immunopharma has a consensus price target of $1.00, suggesting a potential upside of 42.71%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than ImmuCell.
In the previous week, Lyell Immunopharma had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.00 equaled Lyell Immunopharma'saverage media sentiment score.
Summary
ImmuCell beats Lyell Immunopharma on 9 of the 16 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
This page (NASDAQ:ICCC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ICCC Stock Alerts